Synonym
RE 1492; RE-1492; RE1492;
IUPAC/Chemical Name
N,N',N''-(benzene-1,3,5-triyltris(methylene))tris(4-phenylbutan-1-amine)
InChi Key
RPSXXPUMOFOJAV-UHFFFAOYSA-N
InChi Code
InChI=1S/C39H51N3/c1-4-16-34(17-5-1)22-10-13-25-40-31-37-28-38(32-41-26-14-11-23-35-18-6-2-7-19-35)30-39(29-37)33-42-27-15-12-24-36-20-8-3-9-21-36/h1-9,16-21,28-30,40-42H,10-15,22-27,31-33H2
SMILES Code
c1(CNCCCCc2ccccc2)cc(CNCCCCc3ccccc3)cc(CNCCCCc4ccccc4)c1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
561.85
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Rehse K, Ciborski T. Platelet aggregation inhibiting and anticoagulant effects of oligoamines, XXVI: Antiplatelet and antithrombotic effects of the oligoamine RE 1492 in combination with standard and future antithrombotic drugs. Arch Pharm (Weinheim). 1995 Apr;328(4):333-7. PubMed PMID: 7611829.
2: Kesselhut A, Ebel H, von Bruchhausen F, Rehse K. Platelet aggregation inhibiting and anticoagulant effects of oligoamines, XXV: Interactions of the oligoamine RE 1492 with biomembranes. Arch Pharm (Weinheim). 1995 Jan;328(1):21-7. PubMed PMID: 7695469.
3: Rehse K, Müller S. Platelet aggregation inhibiting and anticoagulant effects of oligoamines, XXIX: Influence of the antithrombotic oligoamine RE 1492 on the storage of red blood cells, morphology, their potassium and ATP content, hemolysis and viability. Arch Pharm (Weinheim). 1995 Apr;328(4):339-42. PubMed PMID: 7611830.
4: Neumann M, Müller S, Grosse J, Lerche D, Rehse K. Platelet aggregation inhibiting and anticoagulant effects of oligoamines, XXIII: Influence of the oligoamine RE 1492 on the deformability of red blood cells. Arch Pharm (Weinheim). 1994 Aug;327(8):497-501. PubMed PMID: 7944905.
5: Rehse K, Kaehler H, Kuberka H. [Aggregation inhibiting and anticoagulant effects of oligoamines. 13. Improvement in the storage of whole blood and erythrocyte suspensions with oligoamines]. Arch Pharm (Weinheim). 1990 Aug;323(8):475-9. German. PubMed PMID: 2278513.
6: Rehse K, Ciborski T, Müller B. Platelet aggregation inhibiting and anticoagulant effects of oligoamines, XXVII. Inhibition of leucocyte adherence to endothelium by the oligoamine RE 1492C and the NO-donor RE 2047. Arch Pharm (Weinheim). 1995 Feb;328(2):125-6. PubMed PMID: 7726736.
